期刊文献+

罗格列酮钠对非酒精性脂肪肝大鼠COX-2表达的影响

Effect of Rosiglitazone on the expression of COX-2 protein in non alcoholic fatty liver disease rats
下载PDF
导出
摘要 目的探讨罗格列酮钠(RSG)对高脂诱导的非酒精性脂肪肝(NAFLD)大鼠COX-2表达的影响。方法30只SD大鼠分为对照(CON)组、高脂(HFD)组、RSG组。高脂饮食8w建立大鼠NAFLD模型,建模后,RSG组灌胃3mg·kg-1.d-1RSG,CON组及高脂组灌等量蒸馏水,共12w。测定丙二醛(MDA)、超氧化物歧化酶(SOD)、C反应蛋白(CRP)。光镜观察形态学变化,免疫组化法观察COX-2的表达。结果与CON组相比,HFD组的MDA、CRP升高(P<0.01),SOD降低(P<0.01),HFD组出现明显的脂肪变性(P<0.01),COX-2表达明显增高(P<0.01)。与HFD组相比,RSG组的MDA、CRP降低(P<0.01),SOD升高(P<0.01),肝脏脂肪变性减轻(P<0.01),COX-2表达下降(P<0.01)。结论RSG可以减轻高脂诱导的NAFLD大鼠COX-2的表达,从而减轻NAFLD的炎症。 Objective To explore the effect of Rosiglitazone (RSG) on the expression of COX-2 protein of non alcoholic fatty liver disease (NAFLD) rats induced by high fat diet. Methods Thirty SD rats were divided into control, high fat diet and RSG groups. After the animal model of NAFLD) was induced by fed with high fat diet for 8 weeks, RSG group was treated by garage with RSG for 12 weeks. MDA, SOD and CRP were examined, morphological changes were observed by light microscope, the expression of COX-2 protein was measured by irnmunohistochemistry. Results (1)The levels of MDA and CRP of high fatty diet group were significantly higher and the level of SOD was lower than those of control group (P 〈 0. 01 ). Typical steatosis was aggravated and the expression of COX-2 was increased in high fatty diet group than those in control group. (2) The levels of MDA and CRP of RSG group were significantly lower and the level of SOD was higher than those of high fatty diet group (P 〈 0. 01 ). The degree of liver steatosis was significantly alleviated and the expression of COX-2 was decreased in RSG group than those in high fatty diet group (P 〈0. 01 ). Conclusions RSG could attenuate inflammation reaction of NAFLD by alleviating the expression of COX-2.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2009年第3期301-303,共3页 Chinese Journal of Gerontology
关键词 脂肪肝 干预研究 COX-2 Fatty liver Intervention study COX-2
  • 相关文献

参考文献1

二级参考文献53

  • 1[1]Willner IR,Waters B,Patil SR,Reuben A,Morelli J,Riely CA.Ninety patients with nonalcoholic steatohepatitis:insulin resistance,familial tendency,and severity of disease.Am J Gastroenterol 2001; 96:2957-2961
  • 2[2]Bugianesi E,Leone N,Vanni E,Marchesini G,Brunello F,Carucci P,Musso A,De Paolis P,Capussotti L,Salizzoni M,Rizzetto M.Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma.Gastroenterology 2002; 123:134-140
  • 3[3]Angulo P.Nonalcoholic fatty liver disease.N Engl J Med 2002;346:1221-1231
  • 4[4]Assy N,Kaita K,Mymin D,Levy C,Rosser B,Minuk G.Fatty infiltration of liver in hyperlipidemic patients.Dig Dis Sci 2000; 45:1929-1934
  • 5[5]Green RM.NASH-hepatic metabolism and not simply the metabolic syndrome.Hepatology 2003; 38:14-17
  • 6[6]Angulo P,Keach JC,Batts KP,Lindor KD.Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology 1999; 30:1356-1362
  • 7[7]Donnelly KL,Smith CI,Schwarzenberg SJ,Jessurun J,Boldt MD,Parks EJ.Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.J Clin Invest 2005; 115:1343-1351
  • 8[8]Tamura S,Shimomura I.Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease.J Clin Invest 2005; 115:1139-1142
  • 9[9]Wanless IR,Shiota K.The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases:a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.Semin Liver Dis 2004; 24:99-106
  • 10[10]Maeda N,Shimomura I,Kishida K,Nishizawa H,Matsuda M,Nagaretani H,Furuyama N,Kondo H,Takahashi M,Arita Y,Komuro R,Ouchi N,Kihara S,Tochino Y,Okutomi K,Horie M,Takeda S,Aoyama T,Funahashi T,Matsuzawa Y.Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.Nat Med 2002; 8:731-737

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部